365 related articles for article (PubMed ID: 21338257)
21. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
22. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
Parkinson DR; Johnson BE; Sledge GW
Clin Cancer Res; 2012 Feb; 18(3):619-24. PubMed ID: 22298894
[TBL] [Abstract][Full Text] [Related]
23. Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union.
Pignatti F; Ehmann F; Hemmings R; Jonsson B; Nuebling M; Papaluca-Amati M; Posch M; Rasi G
Clin Cancer Res; 2014 Mar; 20(6):1458-68. PubMed ID: 24634469
[TBL] [Abstract][Full Text] [Related]
24. US FDA and personalized medicine: in vitro diagnostic regulatory perspective.
Težak Ž; Kondratovich MV; Mansfield E
Per Med; 2010 Sep; 7(5):517-530. PubMed ID: 29776248
[TBL] [Abstract][Full Text] [Related]
25. Molecular diagnostics: an FDA perspective.
Ardekani AM; Petricoin EF; Hackett JL
Expert Rev Mol Diagn; 2003 Mar; 3(2):129-40. PubMed ID: 12647991
[TBL] [Abstract][Full Text] [Related]
26. The use of genomics in clinical trial design.
Simon R
Clin Cancer Res; 2008 Oct; 14(19):5984-93. PubMed ID: 18829477
[TBL] [Abstract][Full Text] [Related]
27. US manufacturing guideline for IVD products.
Donawa M
Med Device Technol; 2000 Oct; 11(8):23-4. PubMed ID: 11185183
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacogenomics].
Nakatani K; Nobori T
Rinsho Byori; 2013 Nov; 61(11):1018-25. PubMed ID: 24450107
[TBL] [Abstract][Full Text] [Related]
29. FDA's proposed regulatory approach to regulation of hematopoietic stem/progenitor cell products.
Harvath L
Cytotherapy; 1999; 1(4):358-9. PubMed ID: 20440912
[No Abstract] [Full Text] [Related]
30. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
31. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
32. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
33. Drug development for neglected diseases - the trouble with FDA review vouchers.
Kesselheim AS
N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
[No Abstract] [Full Text] [Related]
34. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
35. An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies.
Beaver JA; Tzou A; Blumenthal GM; McKee AE; Kim G; Pazdur R; Philip R
Clin Cancer Res; 2017 Mar; 23(6):1368-1372. PubMed ID: 27993967
[TBL] [Abstract][Full Text] [Related]
36. The role of the FDA in the effort against AIDS.
Young FE
Public Health Rep; 1988; 103(3):242-5. PubMed ID: 3131814
[TBL] [Abstract][Full Text] [Related]
37. [Discussing the usefulness of companion diagnostics - introductory remarks by chairpersons].
Nobori T; Nomura F
Rinsho Byori; 2014 Dec; 62(12):1263-4. PubMed ID: 25823244
[TBL] [Abstract][Full Text] [Related]
38. Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch.
Scheerens H; Malong A; Bassett K; Boyd Z; Gupta V; Harris J; Mesick C; Simnett S; Stevens H; Gilbert H; Risser P; Kalamegham R; Jordan J; Engel J; Chen S; Essioux L; Williams JA
Clin Transl Sci; 2017 Mar; 10(2):84-92. PubMed ID: 28121072
[TBL] [Abstract][Full Text] [Related]
39. Overcoming regulatory and economic challenges facing pharmacogenomics.
Cohen JP
N Biotechnol; 2012 Sep; 29(6):751-6. PubMed ID: 22370122
[TBL] [Abstract][Full Text] [Related]
40. Regulating molecular diagnostic assays: developing a new regulatory structure for a new technology.
Gibbs JN
Expert Rev Mol Diagn; 2011 May; 11(4):367-81. PubMed ID: 21545255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
